Jaguar Health Inc., a company listed on NASDAQ under the symbol JAGX, has shared insights into its ongoing efforts in developing plant-based medicines for gastrointestinal disorders. The presentation highlights the FDA-approved drug Mytesi, which provides symptomatic relief for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia®-CA1, conditionally approved for treating chemotherapy-induced diarrhea in dogs. A key focus is on Crofelemer, a non-opioid, non-addictive drug that normalizes water flow in the gastrointestinal tract, thereby reducing watery diarrhea and enhancing nutrient absorption. The company also presented Phase 2 data on Crofelemer's use in treating dehydration in cholera patients. You can access the full presentation through the link below.